Trial Profile

A Phase II/III Study of Dalotuzumab (MK-0646) Treatment in Combination With Cetuximab and Irinotecan for Patients With Metastatic Colorectal Cancer

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 09 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dalotuzumab (Primary) ; Cetuximab; Irinotecan
Indications Colorectal cancer
Focus Adverse reactions; Proof of concept; Therapeutic Use
Sponsors Merck Sharp & Dohme

Most Recent Events

15 Jun 2019 This trial has been completed in France, according to European Clinical Trials Database.
01 Sep 2015 Primary endpoint (Overall survival) has not been met according to the results published in the Journal of the National Cancer Institute.
01 Sep 2015 Primary endpoint (Progression-free survival) has not been met according to the results published in the Journal of the National Cancer Institute.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com